Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $298 | In Stock | |
5 mg | $778 | 7-10 days |
Description | Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease. |
Targets&IC50 | IL-33:0.082 nM |
In vitro | Tozorakimab had a > 10,000-fold higher potency for IL-33red than the lead mAb (33v20064) in a biochemical epitope competition assay (IC50=0.082 nM). [1] |
In vivo | Female humanized IL-33 mice (6–10 weeks of age) were anaesthetized using isoflurane. Prophylactic intraperitoneal administration of Tozorakimab (0.1, 1.0, 3.0 and 10.0 mg/kg) dose-dependently inhibited IL-5 levels in bronchoalveolar lavage fluid (BALF) compared with the controls. [1] |
Alias | MEDI-3506, MEDI3506, MEDI 3506 |
Molecular Weight | 144.41 kDa |
Cas No. | 2376858-66-9 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.